Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25324421 | 1.00 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL25325977 | 0.97 | PRMT5 (0.35) | PRMT5WDR77 | |
| SCHEMBL25918684 | 0.88 | PRMT5 (0.39) | PRMT5WDR77 | |
| SCHEMBL30551156 | 0.84 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL25323179 | 0.84 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL25325133 | 0.81 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL30551224 | 0.81 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL25325130 | 0.81 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL25320759 | 0.80 | PRMT5 (0.45) | PRMT5WDR77 | |
| SCHEMBL25320761 | 0.80 | PRMT5 (0.45) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | PRMT5 2082/4885WDR77 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.